drugs to British and Scandinavian patients. The medicines regulator in Spain, the Spanish Agency of Medicines and Medical Devices, confirmed that it had launched an investigation and was gathering evidence. Boehringer Ingelheim, the manufacturer of Nolotil ® , emphasized that it should be available only on prescription and that there was no scientific evidence on specific populations being at greater risk.
Interestingly, almost a decade earlier, Mérida Rodrigo et al 2 had
reported a retrospective analysis of all the patients discharged from
Hospital Costa del Sol (Marbella, Spain) with a main diagnosis of dipyrone-related agranulocytosis from January 1998 to December 2003. Of the 13 cases identified, five were British. These investigators estimated the event rate to be about 2.5-fold higher in the local British population, compared to the overall population, and concluded that the use of dipyrone must be avoided in the British population.
Interethnic differences in drug response have been known for long. The objectives of this commentary are (a) to examine the evidence for the claim of ethnic variability in sensitivity to dipyrone-induced agranulocytosis and (b) to review available key evidence and suggest further investigations.
| COMMENT
The above reports, helpful as they are in raising concern regarding a serious but well-known side effect of a commonly used analgesic, provide a compelling signal for further investigation of claims of interethnic differences in response to dipyrone. Although interethnic differences in drug response have been known for a long time, the current claim relating to dipyrone-induced agranulocytosis is based on anecdotal evidence from spontaneous reports with little reliable epidemiologic data to support it. Whereas spontaneous reports are very helpful in generating a signal or a hypothesis, they are notoriously misleading for actual risk attribution, let alone identify any interethnic differences. Firstly, reports gathered following an appeal on social media are particularly prone to a whole range of biases, depending on the construction and the targeting of the appeal.
Secondly, it seems likely that expatriates suffering unexpected serious events while on holidays may generate or attract greater attention than does the native population with similar events. Finally, not all known cases are reported, particularly in the native population.
Dipyrone-induced agranulocytosis, like a number of other adverse drug reactions, is reported to be approximately twice as frequent in females compared to the males. 3, 4 However, the absence of robust quantitative data on drug usage in most studies makes it difficult to validate any claimed difference in gender-specific susceptibility. In the 161 reports analysed by Stammschulte et al 5 , about two-thirds of the affected patients were females but this was consistent with the gender distribution of dipyrone prescriptions in Germany. This observation underscores the need for reliable data on usage ("denominator") as well as on actual number of cases ("numerator") to enable estimation of incident risk. This is not to diminish the potential significance of the reported apparent increased susceptibility of the three populations to dipyrone-induced agranulocytosis. They may indeed be at a greater risk, but only a well-designed study can provide the necessary confirmation. However, comparing two populations for their relative risks of a serious toxicity presents methodological and ethical challenges when the event rate is low and the duration of treatment to the onset of the event varies widely. Combining data from 158 patients with dipyrone-induced agranulocytosis from two studies, 5, 6 the interval to onset of agranulocytosis was 1-2 days in 33 (21%), 3-21 days in 91 (58%) and more than 21 days in 34 (21%).
These data suggest that potentially two different mechanisms may underpin the complication.
Ibáñez et al 6 suggested that geographical disparities in risk could be partly explained by differences in patterns of dipyrone use in terms of dose, duration and concomitant medications. One study reported that additional risk factors were identified in 24 (36%) of the 66 patients studied, 3 whereas another reported off-label use in 25% of the 161 cases reported. 5 Therefore, from a public health perspective, there is a danger that inadequate documentation of an association of a toxicity with a specific ethnic population may deprive a large subset of that population of a beneficial medication and/or expose that population to an equally unsafe alternative. Current concerns surrounding the use of opioid analgesics are all too familiar. number of metabolites. 9 The half-life of MAA is 2.6-3.5 hours. 10 The concentration-time course of CSF concentrations of MAA is consistent with its plasma concentrations and the analgesic effect of dipyrone. 11 One of the metabolites of MAA is further metabolized by acetylation, but no significant difference was found between rapid and slow acetylators in MAA kinetics. 12 Population pharmacokinetic analysis showed considerable interindividual variability, and age was a significant predictor of the drug's disposition. 13 The potential of dipyrone to induce agranulocytosis has been known since at least 1946. 14 Since then, there have been numerous literature reports of this potentially fatal complication. For example, one 2015 report summarized data on 1417 international and 77 Swiss spontaneous reports of this association. 4 As far as the present author is aware, there is no information on dipyrone-related myelotoxic moiety. Earlier studies on the incidence of dipyrone-induced agranulocytosis show wide geographical variation, 15 5 Apart from its efficacy, one particular advantage of dipyrone compared to NSAIDs is its apparent lack of any teratogenic adverse effects. [21] [22] [23] [24] It is particularly suitable for those in whom NSAIDs are contraindicated or pose a greater risk. 25 It has remained a popular analgesic not only because it is effective but also is generally safer than NSAIDs and opioids 26 and cheap.
For example, the risk of agranulocytosis and pseudo-allergic effect for use in the treatment of heart failure as an adjunct to standard therapy in self-identified Black patients. 29 BiDil ® represents the first medicine to be approved for a specific ethnic group.
It is worth recalling that agranulocytosis following treatment with chlorpromazine is a rare complication that has been reported typically in white Caucasian patients only. HLA alleles have been associated with hypersensitivity reactions, particularly skin reactions, to a number of drugs. 35 They are also associated with agranulocytosis induced by drugs such as le- 
| WHAT IS NE W AND CON CLUS I ON
There is tentative evidence that agranulocytosis from dipyrone may 
| COMPLIAN CE WITH E THIC AL S TANDARDS
This is a commentary on data in the public domain, and the author declares compliance with all ethical standards. 
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